Toxoid Vaccine Market Size Share and Industry Outlook to 2028

SKU: DM2169 | Last Updated On: Nov 29 2021 | No. of Pages: 180 | Available Formats

> Global Toxoid Vaccine Market Expected to reach a high CAGR of 4.9% By 2028: DataM Intelligence

Global Toxoid Vaccine Market is segmented By Disease (Tetanus, Diphtheria, Pertussis), By Composition (Monovalent Tetanus Toxoid, Diphtheria, Tetanus, and Pertussis, Diphtheria and Tetanus), By End-User (Hospitals, Clinics, Government Organizations, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The Global "Toxoid Vaccine Market" is expected to grow at a CAGR of 4.9% during the forecasting period (2021-2028).

Toxoid vaccines are made from a toxin (poison) that has been made harmless but that elicits an immune response against the toxin and used as the antigen in the vaccine to elicit immunity. These vaccines are used to protect against Diphtheria, Tetanus, and pertussis. They create immunity to the parts of the germ that cause disease instead of the germ itself. 

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The global toxoid vaccines market growth is driven by several factors such as rising cases of tetanus and diphtheria, increasing government initiatives for vaccination programs, and growing research & development activities for new vaccines.

Rising number of cases of tetanus and diphtheria is one of the major factors driving the growth of the market, especially in developing economies. According to the WHO, there were 15,103 reported cases in 2018 with an increase from 13,500 tetanus cases in 2016. Tetanus is a non-communicable disease contracted through exposure to the spores of the bacterium, Clostridium tetani. People of all ages can get tetanus but the disease is particularly common and serious in newborn babies and their mothers when the mothers` are unprotected from tetanus by the vaccine, tetanus toxoid. Tetanus toxoid vaccine is used for tetanus prevention by developing immunity against the pathogen causing tetanus. The low cost of tetanus vaccine is also boosting the growth of the market.

In addition, the increasing government initiatives globally are also driving the market growth. These initiatives aim to ensure that every stratum of the society, irrespective of social and economic status is granted access to immunization. For instance, according to WHO report, in 2017, tetanus toxoid (TT) vaccination campaigns targeting women of reproductive age (15–49 years) were conducted in six Member States, reaching an additional 4 million women in 2017. Also, globally, all countries are committed to "elimination" of maternal and neonatal tetanus (MNT), i.e. a reduction of neonatal tetanus incidence to below one case per 1000 live births per year in every district. As of March 2019, 13 countries remain that have not eliminated MNT.

However, the toxoid vaccine market is hampered by several side-effects associated with toxoid vaccine which lowers its preferability. The vaccine causes redness and pain at the site of injection, fever, and fatigue and muscles pains. There are severe allergic reactions of the tetanus toxoid vaccine which occur in less than one in 100,000 people. Also, the bipolar and contractual nature of the toxoid vaccine market leads to fall in profitability of vaccine manufacturing and low demands for these vaccines in the developed regions.

Market Segmentation

On the basis of disease, the market is segmented into tetanus, diphtheria and pertussis. Among these, the tetanus segment held the largets market share in 2018, owing to increasing number of tetanus cases globally. Tetanus is an uncommon but very dangerous disease, of every 10 people who get it, as many as 2 will die and requires treatment in a medical facility, often in a referral hospital. Neonatal tetanus is the most deadly in rural areas where deliveries take place at home without adequate sterile procedures and in unclean environment. According to the WHO, it is estimated that neonatal tetanus killed about 30,848 newborn children in 2017, a 96% reduction from the situation in 1988 when an estimated 787,000 newborn babies died of tetanus within their first month of life. Tetanus is prevented through immunization with tetanus-toxoid-containing vaccines (TTCV). The WHO recommends the use of combination vaccines containing diphtheria toxoid as well, for example Td. Neonatal tetanus can be prevented by immunizing women of reproductive age with TTCV, either during pregnancy or outside of pregnancy. This protects the mother and - through a transfer of tetanus antibodies to the fetus - also her baby. There are two DTaP vaccines available in the United States for the first five doses in children <7 years of age: Daptacel and Infanrix

On the basis of composition the market is segmented into monovalent tetanus toxoid (TT), diphtheria, tetanus, and pertussis (DtaP), diphtheria and tetanus (DT), tetanus and diphtheria (Td) and tetanus, diphtheria, and pertussis (Tdap). Among these, TaP and Dt are estimted to grow significantly over the forecats period. The DTaP and DT vaccine protects young children from diphtheria, tetanus, & whooping cough. The DTaP is formulated with inactivated polio–hepatitis B (Pediarix). Adult Td can be used to vaccinate individuals 7 years and older. Tdap vaccines are available for children between 10 and 18 years of age.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Asia-Pacific toxoid vaccine market is estimated to grow at the highest growth rate during the forecast period (2020-2027), owing to rising number of tetanus and diphtheria, especially in developing countries. The low costs of the vaccine, and increasing government initiatives towards technological improvements regarding immunization and vaccination, are boosting the growth of the toxoid vaccines market in this region. In India, childhood vaccinations were supported with a policy that encouraged women to give birth in sanitary environments. The Indian government offered a payment of $21 for every delivery in a hospital, and women who insisted on a traditional delivery at home were offered free sterilized delivery kits. The National Technical Advisory Group on Immunization (NTAGI), Ministry of Health & Family Welfare has also recommended the replacement of TT vaccine with Td vaccine in India’s immunization programme for all age groups, including pregnant women.

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

The global toxoid vaccines market is highly competitive with presence of smaller and major players. Some of the major players in the market include: Sanofi Pasteur, AstraZeneca Plc, Panacea Biotec, Pfizer, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, Emergent Biosolutions, Bharat Biotech, among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the toxoid vaccines market globally. For instance,

In June 2019, the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Sanofi’s MenQuadfiTM Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine candidate to help prevent meningococcal meningitis. The target action date for the FDA decision is April 25, 2020.

In January 2019, the U.S. FDA has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.

In December 2018, the U.S. FDA has approved VAXELIS(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in children from 6 weeks through 4 years of age. VAXELIS was developed as part of a joint-partnership between Sanofi and MSD (Merck).

Why Purchase the Report?

  • Visualize the composition of the toxoid vaccines market segmentation by disease, composition, and end-user highlighting the key commercial assets and players.

  • Identify commercial opportunities in toxoid vaccines market by analyzing trends and co-development deals.

  • Excel data sheet with thousands of data points of toxoid vaccines market - level 4/5 segmentation.

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key product of all major market players

The global toxoid vaccines market report would provide access to an approx. 57 market data table, 49 figures, and 250 pages.

Target Audience

Trending Topics

DTaP Vaccine Market

BCG Vaccine Market

Flu Vaccine Market

 

Table of Contents

  1. Toxoid Vaccines Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Toxoid Vaccines Market – Market Definition and Overview

  3. Toxoid Vaccines Market – Executive Summary

    1. Market Snippet by Disease
    2. Market Snippet by Composition
    3. Market Snippet by End-User
    4. Market Snippet by Region
  4. Toxoid Vaccines Market – Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. Rising incidence of infectious mononucleosis (IM)
      2. Growing awareness towards mononucleosis
    3. Restraints
      1. Limitations of Available Tests for the Diagnosis of Mononucleosis
    4. Opportunity
    5. Impact Analysis
  5. Toxoid Vaccines Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Product Innovations
    5. Unmet Needs
  6. Toxoid Vaccines Market – By Disease

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Segment
      2. Market Attractiveness Index, By Disease Segment
    2. Tetanus*
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Diphtheria
    4. Pertussis
  7. Toxoid Vaccines Market – By Composition

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Composition Segment
      2. Market Attractiveness Index, By Composition Segment
    2. Monovalent Tetanus Toxoid (TT)*
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Diphtheria, Tetanus, and Pertussis (DtaP)
    4. Diphtheria and Tetanus (DT)
    5. Tetanus and Diphtheria (Td)
    6. Tetanus, Diphtheria, and Pertussis (Tdap)
  8. Toxoid Vaccines Market – By End-User

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
      2. Market Attractiveness Index, By End-User Segment
    2. Hospitals*
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Clinics
    4. Government Organizations
    5. Others
  9. Toxoid Vaccines Market – By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Composition
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Composition
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Composition
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Composition
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Composition
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  10. Toxoid Vaccines Market – Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  11. Toxoid Vaccines Market- Company Profiles

    1. Sanofi Pasteur*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. AstraZeneca Plc
    3. Panacea Biotec 
    4. Pfizer
    5. GlaxoSmithKline
    6. Merck & Co. Inc.
    7. Astellas Pharma Inc.
    8. Valeant Pharmaceuticals
    9. Emergent Biosolutions
    10. Bharat Biotech ("List not exhaustive")
  12. Toxoid Vaccines Market – Premium Insights

  13. Toxoid Vaccines Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables and Figures

List of Tables

Table 1 Global Toxoid Vaccines Market Value, By Disease, 2018,2022 & 2028 ($ Million)

Table 2 Global Toxoid Vaccines Market Value, By Composition, 2018,2022 & 2028 ($ Million)

Table 3 Global Toxoid Vaccines Market Value, By End-User, 2018,2022 & 2028 ($ Million)

Table 4 Global Toxoid Vaccines Market Value, By Disease, 2018,2022 & 2028 ($ Million)

Table 5 Global Toxoid Vaccines Market Value, By Disease, 2017-2028 ($ Million)

Table 6 Global Toxoid Vaccines Market Value, By Composition, 2018,2022 & 2028 ($ Million)

Table 7 Global Toxoid Vaccines Market Value, By Composition, 2017-2028 ($ Million)

Table 8 Global Toxoid Vaccines Market Value, By End-User, 2018,2022 & 2028 ($ Million)

Table 9 Global Toxoid Vaccines Market Value, By End-User, 2017-2028 ($ Million)

Table 10 North America Toxoid Vaccines Market Value, By Disease, 2017-2028 ($ Million)

Table 11 North America Toxoid Vaccines Market Value, By Composition, 2017-2028 ($ Million)

Table 12 North America Toxoid Vaccines Market Value, By End-User, 2017-2028 ($ Million)

Table 13 South America Toxoid Vaccines Market Value, By Disease, 2017-2028 ($ Million)

Table 14 South America Toxoid Vaccines Market Value, By Composition, 2017-2028 ($ Million)

Table 15 South America Toxoid Vaccines Market Value, By End-User, 2017-2028 ($ Million)

Table 16 Europe Toxoid Vaccines Market Value, By Disease, 2017-2028 ($ Million)

Table 17 Europe Toxoid Vaccines Market Value, By Composition, 2017-2028 ($ Million)

Table 18 Europe Toxoid Vaccines Market Value, By End-User, 2017-2028 ($ Million)

Table 19 Asia-Pacific Toxoid Vaccines Market Value, By Disease, 2017-2028 ($ Million)

Table 20 Asia-Pacific Toxoid Vaccines Market Value, By Composition, 2017-2028 ($ Million)

Table 21 Asia-Pacific Toxoid Vaccines Market Value, By End-User, 2017-2028 ($ Million)

Table 22 Asia-Pacific Toxoid Vaccines Market Value, By 0, 2017-2028 ($ Million)

Table 23 Asia-Pacific Toxoid Vaccines Market Value, By 0, 2017-2028 ($ Million)

Table 24 Asia-Pacific Toxoid Vaccines Market Value, By 0, 2017-2028 ($ Million)

Table 25 Middle East & Africa Toxoid Vaccines Market Value, By Disease, 2017-2028 ($ Million)

Table 26 Middle East & Africa Toxoid Vaccines Market Value, By Composition, 2017-2028 ($ Million)

Table 27 Middle East & Africa Toxoid Vaccines Market Value, By End-User, 2017-2028 ($ Million)

Table 28 Sanofi Pasteur: Overview

Table 29 Sanofi Pasteur: Product Portfolio

Table 30 Sanofi Pasteur: Key Developments

Table 31 AstraZeneca Plc: Overview

Table 32 AstraZeneca Plc: Product Portfolio

Table 33 AstraZeneca Plc: Key Developments

Table 34 Panacea Biotec : Overview

Table 35 Panacea Biotec : Product Portfolio

Table 36 Panacea Biotec : Key Developments

Table 37 Pfizer: Overview

Table 38 Pfizer: Product Portfolio

Table 39 Pfizer: Key Developments

Table 40 GlaxoSmithKline: Overview

Table 41 GlaxoSmithKline: Product Portfolio

Table 42 GlaxoSmithKline: Key Developments

Table 43 Merck & Co. Inc.: Overview

Table 44 Merck & Co. Inc.: Product Portfolio

Table 45 Merck & Co. Inc.: Key Developments

Table 46 Astellas Pharma Inc.: Overview

Table 47 Astellas Pharma Inc.: Product Portfolio

Table 48 Astellas Pharma Inc.: Key Developments

Table 49 Valeant Pharmaceuticals: Overview

Table 50 Valeant Pharmaceuticals: Product Portfolio

Table 51 Valeant Pharmaceuticals: Key Developments

Table 52 Emergent Biosolutions: Overview

Table 53 Emergent Biosolutions: Product Portfolio

Table 54 Emergent Biosolutions: Key Developments

Table 55 Bharat Biotech: Overview

Table 56 Bharat Biotech: Product Portfolio

Table 57 Bharat Biotech: Key Developments

 

List of Figures

Figure 1 Global Toxoid Vaccines Market Share, By Disease, 2018 & 2028 (%)

Figure 2 Global Toxoid Vaccines Market Share, By Composition, 2018 & 2028 (%)

Figure 3 Global Toxoid Vaccines Market Share, By End-User, 2018 & 2028 (%)

Figure 4 Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 5 Global Toxoid Vaccines Market Y-o-Y Growth, By Disease, 2018-2028 (%)

Figure 6 Tetanus: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 7 Diphtheria: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 8 Pertussis: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 9 Global Toxoid Vaccines Market Y-o-Y Growth, By Composition, 2018-2028 (%)

Figure 10 Monovalent Tetanus Toxoid (TT): Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 11 Diphtheria, Tetanus, and Pertussis (DtaP): Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 12 Diphtheria and Tetanus (DT): Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 13 Tetanus and Diphtheria (Td): Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 14 Tetanus, Diphtheria, and Pertussis (Tdap): Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 15 Global Toxoid Vaccines Market Y-o-Y Growth, By End-User, 2018-2028 (%)

Figure 16 Hospitals: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 17 Clinics: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 18 Government Organizations: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 19 Others: Global Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 20 North America Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 21 North America Toxoid Vaccines Market Share, By Disease, 2018 & 2028 (%)

Figure 22 North America Toxoid Vaccines Market Share, By Composition, 2018 & 2028 (%)

Figure 23 North America Toxoid Vaccines Market Share, By End-User, 2018 & 2028 (%)

Figure 24 South America Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 25 South America Toxoid Vaccines Market Share, By Disease, 2018 & 2028 (%)

Figure 26 South America Toxoid Vaccines Market Share, By Composition, 2018 & 2028 (%)

Figure 27 South America Toxoid Vaccines Market Share, By End-User, 2018 & 2028 (%)

Figure 28 Europe Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 29 Europe Toxoid Vaccines Market Share, By Disease, 2018 & 2028 (%)

Figure 30 Europe Toxoid Vaccines Market Share, By Composition, 2018 & 2028 (%)

Figure 31 Europe Toxoid Vaccines Market Share, By End-User, 2018 & 2028 (%)

Figure 32 Asia-Pacific Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 33 Asia-Pacific Toxoid Vaccines Market Share, By Disease, 2018 & 2028 (%)

Figure 34 Asia-Pacific Toxoid Vaccines Market Share, By Composition, 2018 & 2028 (%)

Figure 35 Asia-Pacific Toxoid Vaccines Market Share, By End-User, 2018 & 2028 (%)

Figure 36 Middle East & Africa Toxoid Vaccines Market Value, 2017-2028 ($ Million)

Figure 37 Middle East & Africa Toxoid Vaccines Market Share, By Disease, 2018 & 2028 (%)

Figure 38 Middle East & Africa Toxoid Vaccines Market Share, By Composition, 2018 & 2028 (%)

Figure 39 Middle East & Africa Toxoid Vaccines Market Share, By End-User, 2018 & 2028 (%)

Figure 40 Sanofi Pasteur: Financials

Figure 41 AstraZeneca Plc: Financials

Figure 42 Panacea Biotec : Financials

Figure 43 Pfizer: Financials

Figure 44 GlaxoSmithKline: Financials

Figure 45 Merck & Co. Inc.: Financials

Figure 46 Astellas Pharma Inc.: Financials

Figure 47 Valeant Pharmaceuticals: Financials

Figure 48 Emergent Biosolutions: Financials

Figure 49 Bharat Biotech: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest